Tag Archive for: Olumiant

Eli Lilly and Co. agreed to buy Dice Therapeutics Inc. for about $2.4 billion in cash on Tuesday, bolstering its immune disease-related portfolio with a largely oral drug developer.

Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.

For all its forays elsewhere, diabetes remains the bedrock of Lilly’s business – and, if the Mounjaro launch goes as hoped, will continue to be so for a long time to come.

“Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia,” said Kendall Marcus, M.D., director of the Division of Dermatology and Dentistry in the FDA’s Center for Drug Evaluation and Research, adding that the approval fulfills a significant unmet need for patients with severe alopecia areata.